News

Results of the AFIRE study found rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior to combination therapy for safety.

Investigators find that opening all blockages with stents is more beneficial after a heart attack than targeting just the clogged artery causing the event.

New findings from the THEMIS trial show patients with stable coronary artery disease and type 2 diabetes mellitus face major bleeding risks from the combination regimen.

Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.

Results of the PARAGON HF study, which were presented at ESC Congress 2019, reveal no significant benefit of sacubitril-valsartan compared to valsartan for heart failure with preserved ejection fraction in more than 4,500 patients.

A study presented at ESC Congress 2019 revealed childhood BMI, systolic blood pressure, and serum total cholesterol and triglycerides are positively associated with adult CVD.

An updated list of guidelines recommends using catheter ablation to treat supraventricular tachycardia.

The new cardiology guideline provides step-by-step detail to the currently best process of embolism diagnosis.

The European Society of Cardiology and European Association for the Study of Diabetes released new diabetes and cardiovascular guidelines during ESC Congress 2019.

From surgery to pediatrics to neurology, major healthcare innovations have been borne out of sports medicine headlines.

An analysis of questionnaires from more than 3500 players found certain positions and length of career increased a player's risk of developing poor cognitive-related quality of life and mental health.

In honor of National Suicide Prevention Week, Simon Rego, PsyD, and colleagues from Montefiore will look at suicide from a public health and clinical scope.

In a new clinical trial, investigators found a FAAH inhibitor improves the recall of fear extinction memories while reducing the impact of stress in PTSD patients.

From yoga to over-the-counter drugs, numerous options are available for the sleep condition.

Air pollution is driving pediatric risk for lung disease. Are there therapies at hand to address it?

Investigative triple therapy PT010 from AstraZeneca has reached primary outcome results versus a pair of standard dual inhaled therapies.

The FDA warns of liver failure in rare cases from taking Mavyret, Zepatier, and Vosevi to treat hepatitis C.

A recent study found that expanding statin treatment to those with borderline risk of atherosclerotic cardiovascular disease and high LDL-C levels could prevent ASCVD events and be cost-effective on a population level.

Investigators find a gluten-free diet does not cause abdominal pain, reflux, indigestion, diarrhea, and constipation in non-gluten sensitive patients.

A recent review of adverse event reports from the FDA found that tramadol use was associated with a tenfold greater risk of developing hypoglycemia than most other opioids.

CDC data show the infectious respiratory disease has been on a decline since at least 2007—though measures are still needed to address its prevalence in certain populations.

A new set of 22 recommendations include a combination of universal screenings, medication, and other preventative initiatives in an effort to drive down veteran suicide rates.

In a multi-country study, investigators find that the US could reduce the number of deaths for patients waiting for kidney transplants if they accept older kidneys.

A new FDA approval allows istradefylline to be taken as an add-on with other medication to reduce the time medication does not work in Parkinson disease patients.

The SGLT-2 inhibitor is seeking an additional indication for primary renal outcome prevention in patients with or without type 2 diabetes.

A recent study from Northwestern University found that rates of death caused by cardiometabolic disease in the US are no longer in decline and have been rising since 2011.

A study comparing the LABA agent to maintenance therapy showed results supporting recent GINA recommendations for mild asthma management.

Despite a common belief that medications treating mental illnesses are connected to weight gain, new data shows an individual in a weight management program will lose weight whether or not they are taking antidepressants or antipsychotics.